A Phase 1 interventional study of E7080 and E7080 in Non-small-cell Lung Cancer, sponsored by Eisai Co., Ltd.. Completed at 3 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2015-04-30.
Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment
How we know · 10 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 4 under way, 1 of them phase 3. lenvatinib · Carcinoma, Non-Small-Cell Lung.
Among the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, this one is the 8th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 1, and was the 1st registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →3 of the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:
EuroCityClinic LLC · Sites in Russia
Ages 18+
Peking University Cancer Hospital & Institute
Ages 18–80
Peking University First Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 29 across the 14 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 10 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
15 studies in Carcinoma, Non-Small-Cell Lung by Eisai Co., Ltd.: 1 open now, 1 under way, none of them phase 3. Of 14 finished, 10 (71%) have results posted.
Among the 15 studies in Carcinoma, Non-Small-Cell Lung by Eisai Co., Ltd., this one is the 10th largest by enrollment, is the only one that started in 2009, is one of 6 in phase 1, and was the 5th registered.
Eisai Co., Ltd.’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eisai Co., Ltd.’s 15 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determined the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 administered continually twice daily in combination with carboplatin and paclitaxel to patients with advanced or metastatic non-small cell lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Subjects who have ever received the following therapy for non-small cell lung cancer (NSCLC):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin.
Drug: E7080 · Drug: Paclitaxel · Drug: Carboplatin
Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.
Drug: E7080 · Drug: Paclitaxel · Drug: Carboplatin
Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
Maximum Tolerated Dose (MTD)
Tolerability was confirmed by the frequency of occurrence of Dose Limiting Toxicities (DLTs) observed by the end of Cycle 1 in 6 participants.
Time frame: 7 days during the run-in period (Cycle 0) and 3 weeks (21 days) from Cycle 1
Anti-tumor Effect of E7080 in Combination With Carboplatin and Paclitaxel.
Time frame: At Screening, on Day 22 of every even cycle, and at discontinuation
Pharmacokinetics and Pharmacodynamics of E7080 in Combination With Carboplatin and Paclitaxel.
Time frame: At various time points until Day 22 of Cycle 1
To Evaluate the Safety and Tolerability of E7080 in Combination With Carboplatin and Paclitaxel.
Refer safety section for safety analysis
Time frame: Throughout the study until 30 days after last dose
| Milestone | E7080 4 mg BID (Dose Escalation) | E7080 6 mg BID (Dose Escalation) | E7080 4 mg BID (Expansion) |
|---|---|---|---|
| Started | 6 | 6 | 16 |
| Completed | 6 | 5 | 15 |
| Not completed | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
Results for this outcome have not been posted.
Tolerability was confirmed by the frequency of occurrence of Dose Limiting Toxicities (DLTs) observed by the end of Cycle 1 in 6 participants.
| mg BID | E7080 6 mg BID (Dose Escalation) |
|---|---|
| Maximum Tolerated Dose (MTD) | 4 |
Results for this outcome have not been posted.
Refer safety section for safety analysis
Results for this outcome have not been posted.
Collected over Throughout the study until 30 days after last dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E7080 4 mg BID (Dose Escalation) | — | 3/6 (50%) | 6/6 (100%) |
| E7080 6 mg BID (Dose Escalation) | — | 2/6 (33.3%) | 6/6 (100%) |
| E7080 4 mg BID (Expansion) | — | 6/16 (37.5%) | 16/16 (100%) |
| Event | E7080 4 mg BID (Dose Escalation) | E7080 6 mg BID (Dose Escalation) | E7080 4 mg BID (Expansion) |
|---|---|---|---|
| SyncopeNervous system disorders | 0/6 | 1/6 | 0/16 |
| WoundInjury, poisoning and procedural complications | 0/6 | 1/6 | 0/16 |
| HaematomaVascular disorders | 0/6 | 1/6 | 0/16 |
| PneumoniaInfections and infestations | 1/6 | 1/6 | 0/16 |
| Lymphangiosis carcinomatosaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 0/6 | 0/16 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/6 | 0/6 | 0/16 |
| PyelonephritisInfections and infestations | 1/6 | 0/6 | 0/16 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/6 | 0/6 | 2/16 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 1/16 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/6 | 1/16 |
| Event | E7080 4 mg BID (Dose Escalation) | E7080 6 mg BID (Dose Escalation) | E7080 4 mg BID (Expansion) |
|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 6/6 | 5/6 | 15/16 |
| NeutropeniaBlood and lymphatic system disorders | 6/6 | 5/6 | 15/16 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/6 | 4/6 | 16/16 |
| DiarrhoeaGastrointestinal disorders | 6/6 | 4/6 | 12/16 |
| NauseaGastrointestinal disorders | 5/6 | 6/6 | 13/16 |
| Aspartate aminotransferase increasedInvestigations | 4/6 | 6/6 | 5/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/6 | 5/6 | 16/16 |
| Peripheral sensory neuropathyNervous system disorders | 6/6 | 5/6 | 15/16 |
| ProteinuriaRenal and urinary disorders | 6/6 | 3/6 | 11/16 |
| AlopeciaSkin and subcutaneous tissue disorders | 6/6 | 5/6 | 15/16 |
| Age, Continuous(Years) | E7080 4 mg BID (Dose Escalation) | E7080 6 mg BID (Dose Escalation) | E7080 4 mg BID (Expansion) | Total |
|---|---|---|---|---|
| Mean | 52.8 ± 9.3 | 54.8 ± 9.7 | 58.4 ± 11.2 | 56.4 ± 10.4 |
| Sex: Female, Male(Participants) | E7080 4 mg BID (Dose Escalation) | E7080 6 mg BID (Dose Escalation) | E7080 4 mg BID (Expansion) | Total |
|---|---|---|---|---|
| Female | 2 | 2 | 3 | 7 |
| Male | 4 | 4 | 13 | 21 |
The record gives a start of Feb 2009, a primary completion of Jul 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib
Carcinoma, Non-Small-Cell Lung →